- Sector
- Healthcare
- Industry
- Biotechnology
- IPO Date
- Oct 20, 2020
Highlights
- Market Cap
- $1.55B
- Enterprise Value
- $1.35B
- EPS (TTM)
- -$3.85
- Gross Profit (TTM)
- -$1.49M
- EBITDA (TTM)
- -$179.84M
- Year Range
- $5.95 - $62.75
- Target Price
- $28.50
- ROA (TTM)
- -63.90%
- ROE (TTM)
- -100.71%
- Avg. Volume (1M)
- 1M
- Avg. Volume Value (1M)
- $20.69M
Share Price Chart
Loading charts...
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
MLTX Performance Chart
MoonLake Immunotherapeutics (MLTX) is up 39.9% since the beginning of the year. At $18 per share, MLTX is trading 70.6% below its 52-week high of $63. Investors who bought $1,000 worth of MLTX shares 5 years ago would now be looking at an investment worth $1,859.
Loading charts...
Compare this symbol against anything
Returns By Period
MoonLake Immunotherapeutics (MLTX) has returned 39.91% so far this year and -65.15% over the past 12 months.
MoonLake Immunotherapeutics
- 1D
- -2.90%
- 1M
- -2.69%
- 6M
- 17.68%
- YTD
- 39.91%
- 1Y
- -65.15%
- 3Y*
- -31.69%
- 5Y*
- 13.20%
- 10Y*
- —
- ALL TIME*
- 10.87%
Benchmark (S&P 500 Index)
- 1D
- 0.70%
- 1M
- 0.09%
- 6M
- 7.36%
- YTD
- 9.41%
- 1Y
- 20.07%
- 3Y*
- 17.84%
- 5Y*
- 11.25%
- 10Y*
- 13.26%
- ALL TIME*
- 8.09%
MLTX Monthly Returns History
Based on dividend-adjusted daily data since Oct 20, 2020, MLTX's average daily return is +0.25%, while the average monthly return is +4.14%. At this rate, an investment would double in approximately 1.4 years.
Historically, 53% of months were positive and 47% were negative. The best month was Jun 2023 with a return of +87.4%, while the worst month was Sep 2025 at -87.1%. The longest winning streak lasted 6 consecutive months, and the longest losing streak was 4 months.
On a daily basis, MLTX closed higher 48% of trading days. The best single day was Jun 26, 2023 with a return of +77.6%, while the worst single day was Sep 29, 2025 at -89.9%.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | 18.89% | 11.74% | 6.45% | -12.12% | 17.09% | 1.51% | -5.29% | 39.91% | |||||
| 2025 | -15.07% | -9.20% | -6.44% | 7.70% | -7.30% | 20.99% | 6.86% | 10.53% | -87.14% | 40.86% | 35.94% | -4.01% | -75.66% |
| 2024 | -7.47% | -13.67% | 4.13% | -18.55% | -0.61% | 8.14% | -5.28% | 12.34% | 7.76% | -7.93% | 17.26% | -0.51% | -10.33% |
| 2023 | 13.81% | 60.59% | 11.46% | -0.42% | 27.75% | 87.43% | 19.24% | -5.33% | -0.99% | -9.11% | -15.25% | 37.53% | 475.14% |
| 2022 | -0.20% | 0.81% | 11.56% | -44.14% | 24.68% | -32.08% | 20.00% | 27.94% | -3.72% | 6.19% | 20.51% | 5.74% | 6.17% |
| 2021 | -3.25% | 0.00% | -7.27% | -0.88% | -1.09% | 3.50% | -4.17% | -0.39% | 0.71% | 0.50% | -0.70% | -0.40% | -13.02% |
Benchmark Metrics
MoonLake Immunotherapeutics has an annualized alpha of 71.42%, beta of 0.65, and R2 of 0.02 versus S&P 500 Index. Calculated based on daily prices since October 20, 2020.
- This stock participated in 79.27% of S&P 500 Index downside but only 70.98% of its upside - more exposed to losses than it benefited from rallies.
- Beta of 0.65 may look defensive, but with R2 of 0.02 this stock is largely uncorrelated with S&P 500 Index - low beta reflects independence, not downside protection. See the Volatility section for a true picture of this stock's risk.
- R2 of 0.02 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.
- Alpha
- 71.42%
- Beta
- 0.65
- R²
- 0.02
- Upside Capture
- 70.98%
- Downside Capture
- 79.27%
Return for Risk
Risk / Return Rank
MLTX ranks 35 for risk / return — above 35% of stocks peers on PortfoliosLab. Its historical combined result is below the peer median.
Risk / Return Metrics
The table below present risk-adjusted performance metrics for MoonLake Immunotherapeutics (MLTX) and compare them to S&P 500 Index.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| MLTX | Benchmark | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | -1.96 | ||
| Sortino ratioReturn per unit of downside risk | -1.30 | ||
| Omega ratioGain probability vs. loss probability | 1.16 | 1.25 | -0.10 |
| Calmar ratioReturn relative to maximum drawdown | -0.71 | 2.00 | -2.71 |
| Martin ratioReturn relative to average drawdown | -0.93 | 8.49 | -9.42 |
Dividends
Dividend History
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Loading charts...
Worst Drawdowns
The table below displays the maximum drawdowns of the MoonLake Immunotherapeutics. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the MoonLake Immunotherapeutics was 90.22%, occurring on Sep 29, 2025. The portfolio has not yet recovered.
The current MoonLake Immunotherapeutics drawdown is 71.12%.
Drawdown | Fall | Recovery | Underwater | Related event |
|---|---|---|---|---|
-90.22%Sep 2025 | 1y 7mo | — | 2y 5moFeb 2024 - now | — |
-64.60%May 2022 | 1mo 5d | 8mo 27d | 10mo 2dApr 2022 - Feb 2023 | Bear market2022 |
-41.80%Nov 2023 | 1mo 1d | 1mo 21d | 2mo 22dOct 2023 - Dec 2023 | — |
-25.65%Mar 2022 | 1y 1mo | 8d | 1y 1moFeb 2021 - Apr 2022 | Bear market2022 |
-19.79%Apr 2023 | 26d | 20d | 1mo 16dMar 2023 - Apr 2023 | — |
Drawdown Indicators
| MLTX | Benchmark | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -90.22% | -56.78% | -33.44% |
Max Drawdown (1Y)Largest decline over 1 year | -89.93% | -9.10% | -80.83% |
Max Drawdown (3Y)Largest decline over 3 years | -90.22% | -18.90% | -71.32% |
Max Drawdown (5Y)Largest decline over 5 years | -90.22% | -25.43% | -64.79% |
Max Drawdown (10Y)Largest decline over 10 years | — | -33.92% | — |
Current DrawdownCurrent decline from peak | -71.12% | -1.58% | -69.54% |
Average DrawdownAverage peak-to-trough decline | -30.25% | -10.70% | -19.55% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 68.46% | 2.14% | +66.32% |
Volatility
Volatility Chart
The chart below shows the rolling one-month volatility.
Loading charts...
Financials
Financial Performance
The chart below illustrates the trends in the financial health of MoonLake Immunotherapeutics over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.
Valuation
The Valuation section provides an overview of how MoonLake Immunotherapeutics is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.
PB Ratio
The chart illustrates the Price-to-Book (P/B) ratio for MLTX in comparison with other companies in the Biotechnology industry. Currently, MLTX has a P/B value of 5.2. This P/B ratio is in line with the industry average, suggesting the stock is valued fairly in relation to its book value.
Income Statement
| TTM | |
|---|---|
Revenue | |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |
Build a portfolio with MLTX
Add MoonLake Immunotherapeutics to a portfolio and analyze allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Analyzer with MLTX